Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CITALOPRAM AS AN ADJUVANT IN CHRONIC-SCHIZOPHRENIA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
Autore:
SALOKANGAS RKR; SAARIJARVI S; TAIMINEN T; KALLIONIEMI H; LEHTO H; NIEMI H; TUOMINEN J; AHOLA V; SYVALAHTI E;
Indirizzi:
UNIV TURKU,DEPT PSYCHIAT FIN-20520 TURKU FINLAND UNIV TURKU,CENT HOSP,DEPT PSYCHIAT FIN-20520 TURKU FINLAND UNIV TURKU,DEPT BIOSTAT FIN-20520 TURKU FINLAND UNIV TURKU,DEPT PHARMACOL FIN-20520 TURKU FINLAND KUPITTAA HOSP TURIN ITALY OY H LUNDBECK AB TURKU FINLAND
Titolo Testata:
Acta psychiatrica Scandinavica
fascicolo: 3, volume: 94, anno: 1996,
pagine: 175 - 180
SICI:
0001-690X(1996)94:3<175:CAAAIC>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; EXTRAPYRAMIDAL SYMPTOMS; DRUG-INTERACTIONS; FLUOXETINE; NEUROLEPTICS; FLUVOXAMINE; RISPERIDONE; HALOPERIDOL; DEPRESSION; CLOZAPINE;
Keywords:
SCHIZOPHRENIA; CITALOPRAM; NEUROLEPTICS; ANTIDEPRESSANTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
41
Recensione:
Indirizzi per estratti:
Citazione:
R.K.R. Salokangas et al., "CITALOPRAM AS AN ADJUVANT IN CHRONIC-SCHIZOPHRENIA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY", Acta psychiatrica Scandinavica, 94(3), 1996, pp. 175-180

Abstract

The effects of citalopram - the most selective serotonin reuptake inhibitor on the market - on psychopathological symptoms were studied in chronic schizophrenic patients on a stable regimen of neuroleptic medication. Out-patients suffering from schizophrenic disorder (DSM-III-R)with Positive and Negative Symptom Scale (PANSS) scores higher than 50 were included in a double-blind placebo-controlled add-on study. Thedaily dose of citalopram was 20 mg in the first week and 40 mg for the remaining period. A total of 90 patients (45 patients receiving citalopram and 45 receiving placebo) completed the 12-week trial. There were no changes in neuroleptic plasma levels during the trial. There wasa significant decrease in total PANNS scores during the trial, although no statistically significant differences between the citalopram group and the placebo group were revealed. The number of responders in terms of severity of illness (CGI) was higher and the increase in subjective well-being (VAS) was greater in patients on citalopram than in those receiving placebo. There were no significant differences in the occurrence of side-effects. It is concluded that, in chronic schizophrenic out-patients, citalopram has no clear effect on the psychopathological symptoms; it may improve the general clinical condition, and it appears to increase the subjective well-being of these patients. Citalopram appears to be safe when used to treat schizophrenic patients who are receiving concomitant neuroleptic treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 06:29:20